Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma

Elevating the Quality of Cancer Care via Cross-Department Collaboration

A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Ariana Pelosci

Promoting Psychosocial Cancer Care on World Psycho-Oncology Day

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

Most Oncology Nurses Feel Their Post-Pandemic Workload Has Increased

The International Psycho-Oncology Society announced the first-ever WPOD on April 9, 2025, to bring more focus to psychosocial care in cancer therapy.

Related Content

Roman Fabbricatore

Elevating the Quality of Cancer Care via Cross-Department Collaboration

A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Ariana Pelosci

Promoting Psychosocial Cancer Care on World Psycho-Oncology Day

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.